TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03131518

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Access to an e-bicycle with trailer
Description: Participants will be provided with an e-bike with trailer for 3 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Access to a longtail bicycle
Description: Participants will be provided with a longtail bike for 3 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Access to a traditional bike with trailer
Description: Participants will be provided with a traditional bicycle with trailer for 3 months.
Study: NCT02393196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)
Description: Just after spinal anesthesia
Study: NCT00088777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral coping skills training plus physical therapy
Description: 10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management education plus physical therapy
Description: 10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
Study: NCT02874963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Periodontal Treatment
Description: In the patient's with periodontal disease at least one tooth extraction will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Periodontal Treatment
Description: In the patient's with periodontal disease at least one tooth extraction will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.
Description: Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)
Description: Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
Study: NCT06194097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adenoidectomy versus endoscopic sinus surgery with adenoidectomy
Description: adenoidectomy versus endoscopic sinus surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adenoidectomy versus endoscopic sinus surgery with adenoidectomy
Description: adenoidectomy versus endoscopic sinus surgery
Study: NCT04605952

Intervention type: DIAGNOSTIC_TEST
Intervention: Repeat SARS-CoV-2 IgG antibodies at 45-65 days
Description: All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
Study: NCT01207401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1% Lidocaine
Study: NCT02103322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate Tablets, 400 mg
Description: Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate Tablets, 400 mg
Description: Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score.
Study: NCT02168075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25g/kgof 20% mannitol
Description: When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5g/kg of 20% mannitol
Description: When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0g/kg of 20% mannitol
Description: When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5g/kg of 20% mannitol
Description: When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT03179475

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone Naloxone Combination
Description: A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride
Study: NCT05781477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bmum supportive system
Description: Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
Study: NCT00366379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 25-200mg po bid for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 25-200mg po bid for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 25-200mg po bid for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 25-200mg po bid for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 25-200mg po bid for 20 weeks
Study: NCT00125567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo (levodopa/carbidopa/entacapone)
Description: Oral, 50-150 mg levodopa four times daily, for up to 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/carbidopa
Description: Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
Study: NCT05092334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive exercises
Description: proprioception exercises included (a)Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.(b)Gaze stability oculomotor exercises commencing with eyes movement with the head stationary ,progressing to movement of head with visual fixation on a target. (c) Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction
Study: NCT03583944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate IV infusion.
Study: NCT01156922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period.
Study: NCT04397822

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
Study: NCT00228813

Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte Colony Stimulating Factor
Description: FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection
Study: NCT05092334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Description: strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
Study: NCT02412956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmokefreeMOM Text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmokefreeMOM Text
Study: NCT01384474

Intervention type: OTHER
Intervention: Diffusion of a surgical safety checklist
Description: * Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~* A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~  * First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~ * Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~* Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms
Study: NCT05775458

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, CSF and tumor samples
Description: Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
Study: NCT01090232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Study: NCT03019861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ayurvedic nutritional counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional nutritional counseling
Study: NCT02819024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO BID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device for PET
Description: Undergo 18F-FLT PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FLT PET scan
Study: NCT01660750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO on days 1, 8, and 15 every 28 days
Study: NCT02803723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holding-cuddling
Description: The Holding-cuddling is started 5 minutes before veinipuncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: The sucrose adminstration is started 2 minutes before veinipuncture.
Study: NCT01660750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
Study: NCT03382236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathy
Description: osteopathic techniques

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: osteopathy
Description: osteopathic techniques
Study: NCT01871623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental Le Fort I osteotomy
Description: comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-piece Le Fort I Osteotomy
Description: conventional approach
Study: NCT02803723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: The sucrose adminstration is started 2 minutes before veinipuncture.
Study: NCT04062929

Intervention type: BEHAVIORAL
Intervention: 4-day physical activity program with behavioral intervention
Description: Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
Study: NCT01822730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
Study: NCT00925444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FOREseal
Description: a pair of alginate sleeves for linear cutting staplers used in lung surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stapling
Description: Stapling alon or associated with sealants
Study: NCT02550782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patient- controlled infraclavicular perineural marcaine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patient- controlled infraclavicular perineural marcaine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
Study: NCT03340012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTR + radiation-sterilize allogenic bone graft
Description: Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GTR + xenogenic graft
Description: Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
Study: NCT04122963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High power CLOSE-guided PVI ablation
Description: CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CLOSE-guided PVI ablation
Description: Standard AF ablation according to the CLOSE-protocol
Study: NCT04538781

Intervention type: DEVICE
Intervention: VASCADE MVP VVCS
Description: The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
Study: NCT05574218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glycine air powder
Description: Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with glycine powder air-polishing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rubber cup polishing
Description: Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with rubber cup and a polishing paste.
Study: NCT00086177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% progesterone vaginal gel
Description: Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Gel
Description: Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
Study: NCT01699373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: Pre-procedural ultrasound scan was performed
Study: NCT00867529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01640119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Description: bicarbonate administration
Study: NCT04185220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Interleukin-15 (rhIL-15)
Description: Interleukin 15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation 3 + 3 system with a starting dose of 2 mcg/kg/day and a second dose level of 4 mcg/kg/day on days 1-5 of each of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Interleukin-15 (rhIL-15)
Description: Interleukin 15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation 3 + 3 system with a starting dose of 2 mcg/kg/day and a second dose level of 4 mcg/kg/day on days 1-5 of each of six cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab (intravenous (IV) over at least 1 hour) will be administered at a dose of 1 mg/kg on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle. Treatment will continue for a maximum of 6 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab (intravenous (IV) over at least 1 hour) will be administered at a dose of 1 mg/kg on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle. Treatment will continue for a maximum of 6 cycles.
Study: NCT02445248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: The target dose of CTL019 transduced cells for adult patients consisted of a single infusion of 5 x 10\^8 viable CTL019 transduced cells, which was administered via intravenous infusion. The acceptable dose range was 1 - 5x10\^8 viable CTL019 transduced cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle was planned. The use of any additional bridging therapy prior to the recommended lymphodepleting chemotherapy was at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy was started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The lymphodepleting regimen was: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) and cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).
Study: NCT01106560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Anterior Approach
Description: Anterior minimally invasive surgery (AMIS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postero-lateral approach